Why the study?
Do CYP2C19 mutations increase the risk of recurrent cardiovascular events or high on-treatment platelet reactivity in Arab cardiovascular disease patients using clopidogrel?
Population
Arab cardiovascular disease patients using clopidogrel as secondary prophylaxis
Comparison
Carriers of CYP2C19 mutations (*2, *3, *17) vs Non-carriers of CYP2C19 mutations (wild-type)
Design
Meta-analysis
Authors
Loading...
May support CYP2C19 testing in Arab clopidogrel users; extends genetic risk data to this population.
Do CYP2C19 mutations increase the risk of recurrent cardiovascular events or high on-treatment platelet reactivity in Arab cardiovascular disease patients using clopidogrel?
In Arab populations, carriers of CYP2C19*2 and *3 alleles have an approximately 3-fold increased risk of recurrent cardiovascular events when treated with clopidogrel, highlighting the potential utility of pharmacogenetic testing in this demographic.
Sue Barlow (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: